Enrasentan
| Code | Size | Price |
|---|
| TAR-T31640-5mg | 5mg | £1,500.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Enrasentan (sb-217242) is a dual receptor corticosteroid antagonist with a higher affinity for ET (a) receptor, which can reduce blood pressure, prevent cardiac hypertrophy and protect myocardial function.
CAS:
167256-08-8
Formula:
C29H30O8
Molecular Weight:
506.551
Purity:
0.98
SMILES:
CCCOc1ccc2[C@@H]([C@H]([C@@H](c2c1)c1ccc(OC)cc1OCCO)C(O)=O)c1ccc2OCOc2c1
References
1. Prasad SK, Dargie HJ, Smith GC, Barlow MM, Grothues F, Groenning BA, Cleland JG, Pennell DJ. Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study. Heart. 2006 Jun;92(6):798-803. Epub 2005 Dec 9. PubMed PMID: 16339819; PubMed Central PMCID: PMC1860639.
2. Cosenzi A. Enrasentan, an antagonist of endothelin receptors. Cardiovasc Drug Rev. 2003 Spring;21(1):1-16. Review. PubMed PMID: 12595914.
3. Cosenzi A, Bernobich E, Bonavita M, Bertola G, Trevisan R, Bellini G. Antihypertensive treatment with enrasentan (SB217242) in an animal model of hypertension and hyperinsulinemia. J Cardiovasc Pharmacol. 2002 Apr;39(4):488-95. PubMed PMID: 11904522.
4. Willette RN, Anderson KM, Nelson AH, Olzinski AR, Woods T, Coatney RW, Aiyar N, Ohlstein EH, Barone FC. Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction. J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. PubMed PMID: 11588531.